Martina L. Veigl, PhD
Associate Professor, General Medical Sciences (Oncology)email@example.com 216.368.5689 (o) 216.368.8919 (f)
Director of the Gene Expression & Genotyping Core Facility
Case Comprehensive Cancer Center
DNA Mismatch Repair
Li LS, Morales JC, Veigl ML, Sedwick WD, Greer S, Meyers M, Wagner M, Fishel R, Boothman DA. DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new "drugable" targets. Br J Pharmacol. In press, 2009.
Veigl ML, Harris CC. Introduction to a special section: impact of the environment on colon cancer. Environ Mol Mutagen 44:1-2, 2004.
Kaminski BA, Kadereit S, Miller RE, Leahy P, Stein KR, Topa DA, Radivoyevitch T, Veigl ML, Laughlin MJ. Reduced expression of NFAT-associated genes in UCB versus adult CD4+ T lymphocytes during primary stimulation. Blood 102:4608-4617, 2003.
Meyers M, Hwang A, Wagner MW, Bruening AJ, Veigl ML, Sedwick WD, Boothman DA. A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene 22:7376-7388, 2003.
Yan T, Schupp JE, Hwang HS, Wagner MW, Berry SE, Strickfaden S, Veigl ML, Sedwick WD, Boothman DA, Kinsella TJ. Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation. Cancer Res 61:8290-8297, 2001.
Ma AH, Xia L, Littman SJ, Swinler S, Lader G, Polinkovsky A, Olechnowicz J, Kasturi L, Lutterbaugh J, Modrich P, Veigl ML, Markowitz S, Sedwick WD. Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability. Oncogene 19:2249-2256, 2000.
Chen WD, Eshleman JR, Aminoshariae MR, Ma AH, Veloso N, Markowitz SD, Sedwick WD, Veigl ML. Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells. J Natl Cancer Inst 92:480-485, 2000.